Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis

Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis

Complement-mediated damage to the neuromuscular junction (NMJ) is a key mechanism of pathology in myasthenia gravis (MG), and therapeutics inhibiting complement have shown evidence of efficacy in the treatment of MG. In this study, we describe the development of a subcutaneously administered N-acety...

Full description

Bibliographic Details
Main Authors: Linda L. Kusner, Kristina Yucius, Manjistha Sengupta, Andrew G. Sprague, Dhruv Desai, Tuyen Nguyen, Klaus Charisse, Satya Kuchimanchi, Rajeev Kallanthottathil, Kevin Fitzgerald, Henry J. Kaminski, Anna Borodovsky
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050119300452

Internet

http://www.sciencedirect.com/science/article/pii/S2329050119300452

Similar Items